New Medications Are Needed for Children With Juvenile Idiopathic Arthritis.
Hermine I BrunnerLaura E SchanbergYukiko KimuraAnne DennosDominic O CoRobert A ColbertRobert C FuhlbriggeEllen GoldmuntzDaniel J KingsburyCathy Patty-ReskSandra MintzKaren OnelLisa G RiderRayfel SchneiderAllen WattsEmily von SchevenDaniel J LovellTimothy Beukelmannull nullPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2020)
Despite the availability of bDMARDs currently approved for JIA, there is persistent need for additional therapies to control JIA signs and symptoms. Since FDA approval is critical to ensure access to bDMARDs, the study and licensing of new medications is critical to address the unmet medication need and to further improve JIA outcomes.